About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

4.570 -2.160 (-32.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 744,277
Open 4.390
Bid (Size) 4.100 (500)
Ask (Size) 4.570 (3,700)
Prev. Close 6.730
Today's Range 4.100 - 5.400
52wk Range 3.350 - 17.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here are the top movers in Friday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill

Performance

YTD
-65.4%
-65.4%
1 Month
-1.5%
-1.5%
3 Month
-62.8%
-62.8%
6 Month
-57.9%
-57.9%
1 Year
-47.7%
-47.7%

More News

Read More
These stocks are moving in today's pre-market session ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗
Via Stocktwits
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Via Chartmill
News headline image
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
Via Stocktwits
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Leadership Appointments
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
From Aardvark Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 4.570
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 05/15/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.